Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

被引:46
|
作者
Baghaei, Kaveh [1 ,2 ]
Mazhari, Sogol [1 ]
Tokhanbigli, Samaneh [1 ]
Parsamanesh, Gilda [1 ]
Alavifard, Helia [1 ]
Schaafsma, Dedmer [3 ]
Ghavami, Saeid [4 ,5 ,6 ,7 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Basic & Mol Epidemiol Gastrointestinal Disorders, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Gastroenterol & Liver Dis Res Ctr, Tehran 1985717413, Iran
[3] Sci Impact, Winnipeg, MB, Canada
[4] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada
[5] Univ Manitoba, Canc Care Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB R3E 0V9, Canada
[6] Univ Manitoba, Children Hosp Res Inst Manitoba, Biol Breathing Theme, Winnipeg, MB R3E 0V9, Canada
[7] Katowice Sch Technol, Fac Med, PL-40555 Katowice, Poland
关键词
Liver diseases; Extracellular signaling; Cell phenotype; Fibrogenic myofibroblasts; Autophagy; NF-KAPPA-B; HEDGEHOG SIGNALING INHIBITOR; TGF-BETA; ANTIFIBROTIC ACTIVITY; EXTRACELLULAR-MATRIX; RECEPTOR; AUTOPHAGY; PATHWAY; ANGIOGENESIS; PDGF;
D O I
10.1016/j.drudis.2021.12.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatic fibrosis is a manifestation of different etiologies of liver disease with the involvement of multiple mediators in complex network interactions. Activated hepatic stellate cells (aHSCs) are the central driver of hepatic fibrosis, given their potential to induce connective tissue formation and extracellular matrix (ECM) protein accumulation. Therefore, identifying the cellular and molecular pathways involved in the activation of HSCs is crucial in gaining mechanistic and therapeutic perspectives to more effectively target the disease. In addition to a comprehensive summary of our current understanding of the role of HSCs in liver fibrosis, we also discuss here the proposed therapeutic strategies based on targeting HSCs.
引用
收藏
页码:1044 / 1061
页数:18
相关论文
共 50 条
  • [1] CARFILZOMIB SHOWS THERAPEUTIC POTENTIAL FOR REDUCTION OF LIVER FIBROSIS BY TARGETING HEPATIC STELLATE CELL ACTIVATION
    Umemura, Atsushi
    Yamaguchi, Kanji
    Itoh, Yoshito
    HEPATOLOGY, 2024, 80 : S1550 - S1550
  • [2] Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation
    Fujiwara, Ayana
    Takemura, Keisuke
    Tanaka, Anna
    Matsumoto, Misaki
    Katsuyama, Masato
    Okanoue, Takeshi
    Yamaguchi, Kanji
    Itoh, Yoshito
    Iwata, Kazumi
    Amagase, Kikuko
    Umemura, Atsushi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [3] Regulatory Functions and Mechanisms of Circular RNAs in Hepatic Stellate Cell Activation and Liver Fibrosis
    Nokkeaw, Archittapon
    Thamjamrassri, Pannathon
    Tangkijvanich, Pisit
    Ariyachet, Chaiyaboot
    CELLS, 2023, 12 (03)
  • [4] Mechanisms of NLRP3 inflammasome- mediated hepatic stellate cell activation: Therapeutic potential for liver fibrosis
    Charan, Harsh Vardhan
    Dwivedi, Durgesh Kumar
    Khan, Sabbir
    Jena, Gopabandhu
    GENES & DISEASES, 2023, 10 (02) : 480 - 494
  • [5] Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
    Barcena-Varela, Marina
    Colyn, Leticia
    Fernandez-Barrena, Maite G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (10)
  • [6] Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis
    Duval, Florent
    Moreno-Cuevas, Jorge E.
    Gonzalez-Garza, Maria Teresa
    Rodriguez-Montalvo, Carlos
    Elva Cruz-Vega, Delia
    CHINESE MEDICINE, 2014, 9
  • [7] Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis
    Florent Duval
    Jorge E Moreno-Cuevas
    María Teresa González-Garza
    Carlos Rodríguez-Montalvo
    Delia Elva Cruz-Vega
    Chinese Medicine, 9
  • [8] Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis
    Garbuzenko, Dmitry Victorovich
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (12) : 3662 - 3676
  • [9] Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis
    Dmitry Victorovich Garbuzenko
    World Journal of Clinical Cases, 2022, (12) : 3662 - 3676
  • [10] Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ
    Liu, Fangbin
    Li, Shengnan
    Chen, Panpan
    Gu, Yanqiu
    Wang, Shaozhan
    Wang, Lei
    Chen, Chun
    Wang, Rong
    Yuan, Yongfang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122